Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2026

This bill would require federal agencies that fund research to include a condition in their research agreements, and in licenses for related patents or test data, that any drug, vaccine, medical device, test, or other health technology developed with that research be sold at a reasonable price, as determined by the Secretary of Health and Human Services. U.S. residents could not be charged more than the median price in Canada and six other large, high-income countries. The Secretary could add other pricing rules or grant waivers after public notice, comment, and an economic analysis. Companies selling these products would have to report clinical trial costs, federal subsidies, and annual revenues, and the Secretary would make those reports public.

Full text and official record on Congress.gov

Sponsors

• Val T. Hoyle Democrat sponsor
• 15 cosponsors